home / stock / idxx / idxx articles
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 15 years by 14.19% on an annualized basis producing an average annual re...
IDEXX Laboratories Inc (NASDAQ: IDXX) reported Q3 FY23 sales of $915.53 million, missing the consensus of $926.76 million. Adjusted EPS w...
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 20 years by 4.28% on an annualized basis producing an average annual ret...
Stifel analyst Jonathan D. Block reiterated a Hold rating on IDEXX Laboratories, Inc. (NASDAQ: IDXX), lowering the price target...
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 15 years by 10.94% on an annualized basis producing an average annual re...
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 10 years by 16.16% on an annualized basis producing an average annual re...
News, Short Squeeze, Breakout and More Instantly...
IDEXX Laboratories Inc. Company Name:
IDXX Stock Symbol:
NASDAQ Market:
IDEXX Laboratories Inc. Website:
2024-06-28 23:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 second quarter results for Tuesday, August 6, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. ...
2024-06-24 08:00:11 ET Jonathan Block from Stifel Nicolaus issued a price target of $510.00 for IDXX on 2024-06-24 07:19:00. The adjusted price target was set to $510.00. At the time of the announcement, IDXX was trading at $495.73. The overall price target consensus is ...